Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5
Case ID:
TAB-3201
Web Published:
12/6/2022
A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Conformation_Dependent_Anti- major_Outer_Membrane_Protein_(MOMP)_Monoclonal_Antibody_BD5
Keywords:
Against
ANTIBODY
Anti-major
B
ba
BD5
Chlamydia
CONFORMATION
Correct
D
Dependent
e
Hybridoma
L2
Listed LPM Thalhammer-Reyero as of 4/15/2015
Mab
MEMBRANE
MOMP
monoclonal
OUTER
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
Protein
RM
SEROVARS
TRACHOMATIS
USEFUL
vaccines
Verifying
WIXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Charles Rainwater
Technology Development Specialist
NIH Technology Transfer
301-496-5717
crainwater@mail.nih.gov